Immunotherapy plus targeted therapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- This trial is for people newly diagnosed with advanced kidney cancer that has spread to other parts of the body.
- You must have a kidney tumor that can be biopsied and the biopsy must show a specific immune cell pattern (called TLS).
- You must not have had any prior systemic treatment for advanced kidney cancer.
- You must be able to take oral medication and have adequately controlled blood pressure.
- You must be willing to undergo repeat biopsies and imaging scans as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
This trial tests a combination of two drugs—an immunotherapy called toripalimab and a targeted therapy called axitinib—for people with rare kidney cancers that have spread. The goal is to see if this combination can shrink or control the cancer before any surgery to remove the kidney.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.